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The safety, pharmacokinetics, and antiretroviral activity of lamivudine alone and in com-
bination with zidovudine was studied in pregnant women infected with human immunode-
ficiency virus type 1 (HIV-1) and their neonates. Women received the drugs orally from week
38 of pregnancy to 1 week after delivery. Neonate therapy began 12 h after delivery and
continued for 1 week. Both treatment regimens were well-tolerated in women and newborns.
Lamivudine and zidovudine pharmacokinetics in pregnant women were similar to those in
nonpregnant adults. Lamivudine and zidovudine freely crossed the placenta and were secreted
in breast milk. Neonatal lamivudine clearance was about half that in pediatric patients; zi-
dovudine clearance was consistent with previous reports. HIV-1 RNA could be quantified in
17 of the 20 women. At the onset of labor/delivery, mean virus load had decreased by ∼1.5
log10 copies/mL in both treatment cohorts. Although not definitive for HIV-1 infection status,
all neonates had HIV-1 RNA levels below the limit of quantification at birth and at ages 1
and 2 weeks.
In a placebo-controlled clinical trial in the United States and
France (AIDS Clinical Trial Group [ACTG] 076) in subjects
infected with human immunodeficiency virus type 1 (HIV-1),
zidovudine given during pregnancy and delivery and to neo-
nates substantially reduced the transmission of HIV-1 infection
from 25.5% to 8.3% [1]. This regimen, however, is impractical
in developing countries for a number of reasons. In ACTG 076,
subjects received treatment from weeks 14–34 of gestation,
whereas in developing countries, pregnant women often pre-
sent at an antenatal clinic very late in pregnancy. Also, the cost
of a lengthy regimen with an intravenous component during
labor would be prohibitive in cost in this setting. Finally, ACTG
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076 was conducted in a non–breast-feeding population. Given
the risk of HIV-1 transmission through breast-feeding [2–4], the
efficacy of the ACTG 076 regimen is unknown in a breast-
feeding population.
In addition, because evidence suggests that most maternal-
fetal HIV-1 transmission occurs late in pregnancy and during
delivery [5, 6], a short, practical, and affordable regimen in a
breast-feeding population needs to be investigated. The com-
bination of lamivudine and zidovudine has an established safety
profile in adults and children 13 months of age, and the safety
of zidovudine has been established in neonates [7, 8]. Treatment
in naive adults results in a 1.5 log10 reduction in virus load after
2 weeks [9]. The combination would therefore seem to be po-
tentially useful in the prevention of maternal-fetal transmission,
although there are no data on therapy with lamivudine-zido-
vudine combination therapy in pregnant women or neonates.
This study was designed to provide information on the safety
and pharmacokinetics of lamivudine alone and in combination
with zidovudine in pregnant women and their neonates. The
data produced were to be used specifically to recommend la-
mivudine regimens on the basis of pharmacokinetic exposure
for use in subsequent efficacy studies, including the Joint United
Nations Programme on HIV/AIDS (UNAIDS)–sponsored
perinatal transmission (PETRA) study. A further objective was
to assess the antiviral activity of combined lamivudine and
zidovudine in pregnant women, although this information was
superseded by that from a subsequent efficacy study. Finally,
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where sufficient sample volume remained after lamivudine
bioanalysis, zidovudine concentrations were assessed for phar-
macokinetic evaluation.
Materials and Methods
Subjects. Twenty pregnant HIV-1–positive women who were
otherwise free of significant disease were enrolled in this study.
Primary exclusion criteria were multiple pregnancies; pregnancy
complications or anticipated elective cesarean section; significant
laboratory abnormalities, including hemoglobin levels !8 g/dL be-
fore entry; and previous antiretroviral therapy. After delivery, the
20 neonates were enrolled in the study.
Design. This was a single center (Durban, South Africa), phase
II, open-label, repeat-dose, randomized, two-way, parallel-group
study. Two groups of 10 women received either lamivudine alone
(300 mg twice daily) or lamivudine (150 mg twice daily) with zi-
dovudine (300 mg twice daily) before delivery (from 38 weeks ges-
tation), intrapartum, and for 1 week after delivery. At the onset of
labor, the women received either a single 300-mg lamivudine dose
or 150 mg of lamivudine with 300 mg of zidovudine orally. La-
mivudine oral dosing was continued every 12 h during labor.
Women assigned to combination therapy also were given 300 mg
of zidovudine orally every 3 h until delivery. In the absence of any
life-threatening condition or severe laboratory abnormality, neo-
nates were treated for 1 week in accordance with their mother’s
randomization, commencing 12 h after delivery. Neonates were
given lamivudine orally—alone (4 mg/kg twice daily) or in com-
bination with zidovudine (2 mg/kg 4 times/day).
Safety assessments. All women received full medical exami-
nations, and hematologic and biochemical analyses were done
throughout the study. Clinical adverse events were monitored con-
tinuously with standard intrapartum fetal monitoring. Infants were
examined postpartum and received regular clinical examinations
to age 12 months. Neonates had hematologic and biochemical anal-
yses to age 6 weeks.
Maternal sampling. Serum samples were analyzed initially to
determine lamivudine concentrations and if sample volumes per-
mitted, zidovudine concentrations were also determined. Blood
samples were collected on day 1 of therapy (week 38 of gestation),
before drug administration (predose), at 30 min and at 1, 2, 4, 8,
and 12 h after drug administration (postdose), and at the start of
labor and every 6 h thereafter. At birth, samples were obtained of
maternal blood, amniotic fluid (when possible), and cord blood
upon clamping. One week postpartum, a full profile (as on day 1)
was collected with an additional 24-h postdose sample. Where pos-
sible, breast-milk samples (0.5–5 mL) were taken daily before
feeding.
Neonatal sampling. Serum samples for determination of drug
concentration were collected at birth (to coincide with the maternal
sampling/cord clamping); at 1, 3, 8, and 12 h after birth; before
therapy on days 6 and 7; and 1, 3, 8, 12, and 24 h postdose on
day 7.
Serum, breast milk, and amniotic fluid samples were analyzed
for lamivudine by a validated high-performance liquid chroma-
tography method using UV detection [10]. The assay has a lower
limit of quantification of 20 ng/mL. Serum and breast milk samples
were analyzed for zidovudine by a validated RIA commercial kit
(Zidovudine-Trac; IncStar, Stillwater, MN).
Pharmacokinetic and statistical analysis. The maximum drug
concentration in serum (Cmax) and the time to Cmax (tmax) were
obtained directly from the concentration-time data. The terminal
serum half-life (t1/2), area under the concentration-time curve
(AUC), and oral clearance (CL/F) were calculated by model in-
dependent analysis (WinNONLIN version 1.1; Scientific Consult-
ing, Cary, NC). All analyses used SAS software (version 6.08; SAS,
Cary, NC).
Antiretroviral activity. During the first day of drug therapy,
maternal plasma samples for virologic analysis were obtained be-
fore treatment and at 4, 8, 12, and 24 h after therapy. Further
samples were obtained during pregnancy and labor, at birth, and
at 1 and 2 weeks after birth. Neonatal samples were collected at
birth and at 1 and 2 weeks after birth. Quantitative polymerase
chain reaction (PCR) was done on maternal and neonatal plasma
(Amplicor; Roche Diagnostics, Nutley, NJ) [11]. The resulting
PCR fragments were sequenced using the fluorescein sulphonate
dye terminator kit (Applied Biosystems, Foster City, CA). Products
were analyzed by automated DNA sequencer (model 373; Applied
Biosystems).
Results
Patient Demographics
All women were 18- to 34-year-old black Africans. Three
women in the group given combination therapy were CDC
class B at entry; all others were CDC class A. Maternal and
neonatal demographics in both groups were similar. The time
between the first dose of drug(s) and birth varied widely (0–28
days) with a median of 13.7 days in the lamivudine group and
15.7 in the combination therapy group.
Safety
Both lamivudine and lamivudine plus zidovudine were well-
tolerated. No woman or neonate discontinued treatment be-
cause of an adverse event, and no serious adverse events were
considered related to study medication. In 1 mother given la-
mivudine monotherapy, hemoglobin declined from 7.8 g/dL at
entry to 6.5 g/dL at delivery.
Two neonates died at ages 5 and 6 months during follow-
up; neither death was considered related to study drug. Four
neonates experienced serious adverse events; however, after in-
vestigation, these were not considered treatment-related: acute
renal failure, meconium aspiration, gastroenteritis, and
jaundice.
Two neonates had “nonserious” adverse events that may
have been treatment-related. One neonate, who received com-
bination therapy, had a rash on day 6 of therapy, which resolved
in 2 days. Another, who received lamivudine alone, had mild
anemia (hemoglobin: 9.1 g/dL) at age 6 weeks, which resolved.
Other unrelated adverse events were mainly ear, nose, and
throat and lower respiratory tract infections.
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Figure 1. Lamivudine and zidovudine (mean 5 SD) serum con-
centration vs. time in pregnant women at week 38 of gestation after
single oral dose: 300 mg of lamivudine (V), 150 mg of lamivudine 1
zidovudine (M), or 300 mg of zidovudine 1 lamivudine (n).
Table 1. Maternal prepartum (single dose) and postpartum (steady-state) lamivudine
(LAM) pharmacokinetic parameters after oral dose of drug.
Drug given
LAM monotherapy
(300 mg twice/day)
LAM plus zidovudine
(150 mg twice/day) Comparisona
Before delivery (first dose)
AUC (ng/h/mL)b 10,047 (8482–11,921) 4933 (3997–6089) 1.02 (0.83–1.25)
Cmax (ng/mL)
b 2504 (1996–3140) 1313 (1070–1610) 0.95 (0.75–1.20)
tmax (h) 1.5 (0.5–2.0) 1.0 (0.5–2.0) —
CL/F (L/h/kg) 0.41 (0.34–0.49) 0.44 (0.35–0.55) 0.94 (0.75–1.17)
t1/2 (h) 2.3
b (2.0–2.6) 2.3b (2.0–2.7) 0.99 (0.85–1.14)
1 week postpartum
AUC (ng/h/mL)b 9896 (7832–12,505) 5082 (3749–6889) 0.97 (0.73–1.31)
Cmax (ng/mL)
b 2433 (1761–3363) 1210 (981–1492) 1.01 (0.75–1.35)
tmax (h) 1.0 (0.5–4.0) 1.5 (0.5–4.0) —
CL/F (L/h/kg) 0.45 (0.35–0.58) 0.46 (0.32–0.66) 0.98 (0.70–1.37)
t1/2 (h) 5.9 (4.1–8.7) 6.6 (4.9–9.2) 0.90 (0.62–1.32)
NOTE. Data are geometric least square mean (95% confidence interval); tmax, median (range);
AUC 5 area under curve (to infinity for single dose, prepartum, and to dosing interval [t], post-
partum); Cmax 5 observed peak concentration; tmax 5 time of peak concentration; CL/F 5 oral
clearance, t1/2 5 half-life.
a Geometric least-squares mean ratio (90% confidence interval).
b AUC and Cmax dose-normalized for comparisons.
c Half-life estimate underpredicted due to truncated sampling at 12 h (dosing interval).
Pharmacokinetics
Lamivudine. Maternal pharmacokinetic parameter esti-
mates for lamivudine at either week 38 of pregnancy (first dose)
or after repeated twice-daily doses for 1 week after delivery
(table 1, figure 1) showed no interaction between lamivudine
and zidovudine. The lamivudine accumulation ratio following
repeated twice-daily dosing ranged from 1 to 1.4 with a dom-
inant elimination half-life of 5–7 h.
Mean concentrations of lamivudine in serum, amniotic fluid,
and breast milk for lamivudine monotherapy were 550 ng/mL
(range, 102–2520), 1.83 mg/mL (range, 1.2–2.5), and 1.22 mg/
mL (range, !0.5–6.09), respectively. Similar results were re-
corded for lamivudine in the combination group: 301 ng/mL
(range, 183–883), 3.85 mg/mL (range, 2.1–5.2), and 0.9 mg/mL
(!0.5–8.2).
Following birth, the terminal elimination rate was similar
between treatment groups (figure 2). The mean lamivudine
elimination half-life (or washout) in neonates immediately after
birth was 13.95 h (range, 6.2–35.1). Lamivudine concentrations
for mother, cord blood, and the neonate at birth were very
similar to therapeutic doses with maternal–cord blood–neonate
ratios near unity. Median (range) times between last treatment
dose and onset of labor for the combination group was 11.6 h
(0.7–13.9) and 7.1 h (0.7–13.0) between last treatment dose and
birth. The median (range) lamivudine concentration at the on-
set of labor in this treatment group was 165 ng/mL (range,
83–1150).
Lamivudine pharmacokinetics in neonates at age 1 week did
not differ with or without zidovudine administration (table 2,
figure 3). After twice-daily dosing for 1 week, lamivudine oral
clearance in neonates was ∼0.4 L/h/kg.
Zidovudine. Zidovudine pharmacokinetic parameter esti-
mates (Cmax, tmax, and t1/2) at week 38 of pregnancy (single dose)
were 1607 ng/mL, 0.5 h, and 1.7 h, respectively. These param-
eters were similar to those calculated at postpartum week 1
(multiple dose). The AUC and CL/F for the single prepartum
dose were 2533 ng/h/mL and 119 L/h, and both of these pa-
rameters differed significantly ( ) from the repeat post-P ! .05
partum steady-state dosing parameters: 4179 ng/h/mL and 72
L/h. The geometric least-squares mean ratios for AUC and CL/
F were 1.65 and 0.61, respectively. Average zidovudine steady-
state concentration after delivery was 357 ng/mL.
The median (range) concentration at the onset of labor was
20.23 ng/mL (11.32–324.67) before a 300-mg zidovudine load-
ing dose: A loading dose was given if the preceding dose was
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Figure 2. Lamivudine and zidovudine (mean 5 SD) deviation
serum concentration vs. time in neonates at birth. Lamivudine mono-
therapy (V), lamivudine 1 zidovudine (M), and zidovudine 1 lamivu-
dine (n).
16 h earlier. Oral zidovudine intrapartum lamivudine therapy
was predicted to provide an average concentration of ∼860 ng/
mL. Serum zidovudine concentrations at birth were similar
between mother, cord blood, and neonate after oral zidovu-
dine administration; median concentrations were 261, 379, and
307 ng/mL, respectively. The median (range) time from last
zidovudine dose administered during labor to birth sample was
2.34 h (0.50–7.17). The median (range) cord–maternal se-
rum–zidovudine ratio at birth was 1.61 (0.92–2.47), and the
neonate–maternal serum–zidovudine ratio at birth was 1.22
(0.31–1.69).
Table 2 shows steady-state zidovudine pharmacokinetic
parameters in the neonates. After zidovudine was given for 1
week (2 mg/kg every 6 h), zidovudine elimination, based on
terminal elimination half-life, was significantly more rapid than
seen immediately after birth. The median (range) zidovudine
terminal elimination half-life in neonates after 1 week of zi-
dovudine treatment was 3.2 h (2.5–4.4). Neonatal (mean 5
) zidovudine CL/F was mL/min/kg (coefficientsSD 18.1 5 11.7
of variation, 64%) after oral administration for 1 week.
Antiretroviral Activity
Predose HIV-1 RNA levels were slightly higher in the group
randomized to receive lamivudine monotherapy (4.1 log10
HIV-1 RNA copies/mL) than in the group randomized to re-
ceive lamivudine plus zidovudine (3.7 log10 HIV-1 RNA copies/
mL) as shown in table 1. Three women (1 assigned to lami-
vudine monotherapy and 2 to lamivudine plus zidovudine) had
HIV-1 RNA levels below the limit of detection at study entry
(∼400 RNA copies/mL). Average predose virus loads for all
groups were similar and slightly higher (4.4 and 4.2 log10 for
lamivudine monotherapy and for lamivudine plus zidovudine,
respectively.)
Both cohorts showed broadly similar changes in virus load
following therapy (figure 4). Levels of HIV-1 RNA were vir-
tually unchanged over the first 24 h of therapy regardless of
assigned treatment group. During the first week of therapy, an
average reduction of plasma HIV-1 levels 110-fold (1 log10) was
observed in both the lamivudine monotherapy and combina-
tion groups. There was a large variation in the length of treat-
ment before the onset of labor (median, 16 days; range, 0–28).
By the onset of labor, mean virus reduction was 11.5 logs in
both groups, and this reduction was virtually unchanged at
delivery. When the 3 women who were below the limit of quan-
titation before therapy were excluded, ∼25% and ∼75% of
women had !500 HIV-1 RNA copies/mL at the start of labor
and at delivery in the monotherapy and combination groups,
respectively. It is important to note, however, that the lami-
vudine monotherapy group had higher baseline levels of HIV-
1 and were treated an average of 2 days less before the start
of labor.
In the lamivudine monotherapy arm, maternal virus load
was ≤3 log10 (1000 copies/mL) for all patients but 2 at deliv-
ery. One of the 2 began labor on the day that she was to begin
therapy; the other showed a rebound in virus load. Patients
assigned to the lamivudine plus zidovudine arm also had large
reductions in HIV-1 load over the first days of therapy. At
delivery, maternal virus load was ≤3 log10 (1000 copies/mL) for
all patients receiving combination therapy, and there was little
sign of rebound in virus load in these patients. Further reduc-
tions in mean virus load at 1 and 2 weeks after delivery indicate
that peak reductions in maternal virus load did not occur before
delivery.
Two patients assigned to lamivudine monotherapy had evi-
dence of virus rebound, 1 before and 1 after delivery. In both,
the rebound was characterized by a predominance of virus with
M184 Val substitution.
HIV-1 RNA could not be detected in the neonates at birth
or 1 or 2 weeks after birth. At 12 months of follow-up, 15
babies were HIV antibody–negative and 1 was antibody posi-
tive by ELISA. Two died of nondrug- or HIV-1–related inci-
dents, and 2 were lost to follow-up prior to the 9- and 12-
month evaluations.
Discussion
Lamivudine alone and with zidovudine was well-tolerated in
the women treated and in their neonates. No serious adverse
events were considered related to the antiretroviral therapy in
the mothers or infants. Laboratory results, including hemoglo-
bin levels, in this small group of patients did not raise signifi-
cant concerns. In particular, oral intrapartum therapy was
well-tolerated and no nausea or vomiting were reported.
Pharmacokinetics. Lamivudine pharmacokinetic param-
JID 1998;178 (November) Lamivudine Pharmacokinetics in Pregnancy and Newborns 1331
Figure 3. Lamivudine and zidovudine (mean 5 SD) deviation
serum concentration vs. time in neonates after steady-state oral treat-
ment. Lamivudine: 4 mg/kg 2 times/day (V), lamivudine 4 mg/kg 2
times/day 1 zidovudine (M), and zidovudine 2 mg/kg 4 times/day 1
lamivudine (n).
Table 2. Neonatal steady-state pharmacokinetic parameters following oral administration of lami-
vudine (LAM) for 1 week.
LAM
Comparisona
AZT with LAM
(2 mg/kg 4 times/day)
Monotherapy
(4 mg/kg twice/day) With AZT
AUCt (ng/h/mL) 16,883 (13,395–21,278) 15,627 (12,367–19,746) 1.07 (0.85–1.33) 2151 (1355–3416)
Cmax (ng/mL) 1969 (1671–2321) 1689 (1288–2218) 1.17 (0.91–1.49) 493.82 (313–780)
Tmax (h) 3.0 (1.0–8.0) 3.0 (1.0–3.0) — 3.0 (0.9–3.1)
CL/F (L/h) 1.1 (0.9–1.3) 1.2 (0.8–1.6) 0.90 (0.71–1.14) 3.1 (1.9–5.1)
t1/2 (h) 6.0 (5.1–6.8) 6.6 (5.3–7.9) 0.90 (0.76–1.07) 3.3 (2.6–4.3)
NOTE. Data are geometric least square mean (95% confidence interval); tmax, median (range); AUC 5 area under
curve (to dosing interval [t]); Cmax 5 observed peak concentration; tmax 5 time of peak concentration; CL/F 5 oral
clearance, t1/2 5 half-life; AZT 5 zidovudine.
a Geometric least-squares mean ratio (90% confidence interval).
eter estimates at week 38 of pregnancy, at 1 week after delivery,
and in combination with zidovudine were similar to previous
estimates in nonpregnant adults and demonstrate the lack of
effect of pregnancy or combination therapy on lamivudine dis-
position. Consequently, no dose modification should be re-
quired. The concept of a loading dose at the onset of labor
(given if the preceding dose was 16 h earlier) was introduced
to ensure that all women, regardless of variability in phar-
macokinetic disposition, achieved adequate serum concentra-
tions intrapartum. Lamivudine was present (trough concen-
ng/mL) in all mothers through labor with ourtrations 5 80
regimen. Results from the high-dose lamivudine monother-
apy group (300 mg twice/day) showed that 300 mg was safe
and well-tolerated in this patient group. There were no increases
in incidence or severity of adverse events causally related to
treatment. Consequently, a 150-mg lamivudine and a 300-mg
zidovudine loading dose at the onset of labor should not pre-
sent any clinical concern and should ensure adequate serum
concentrations through this important period as previous
compliance may be unknown.
Although sampling was limited, maternal zidovudine con-
centrations decayed in a biexponential manner. Maternal zi-
dovudine pharmacokinetic parameters at week 38 of pregnancy
were similar to those previously observed in adult males and
in nonpregnant females. Zidovudine pharmacokinetic param-
eter estimates for AUC and CL/F differed between late preg-
nancy and 1 week postpartum; these results were similar to
others in 3 patients studied before delivery and 3–4 weeks post-
partum [12] and may be a consequence of physiologic changes
following birth.
The 300-mg zidovudine regimen taken orally every 3 h with
a loading dose at the onset of labor was based on theoretical
considerations to obtain exposures comparable to those in the
ACTG 076 intravenous regimen. Maternal, cord blood, and
neonatal zidovudine concentrations at birth presented in this
report and in a study in Thailand that used the same oral
regimen were also similar to the intermittent infusion dosing
schedule reported in ACTG 082 [13, 14]. The average predicted
zidovudine concentration during labor with the oral inter-
mittent regimen in this study was similar to that reported
with a continuous infusion regimen (at the end of infusion),
and ng/mL, respectively.∼ 860 5 180 1020 5 900
At birth, concentrations of lamivudine and zidovudine were
similar in maternal, cord, and neonatal serum, illustrating free
passage across the placenta. This is not unexpected given that
both drugs are extensively distributed, have a relatively low
molecular weight, and display limited plasma protein binding.
In addition, ex vivo human placenta data support passive dif-
fusion of lamivudine and zidovudine [15, 16].
Lamivudine was present in amniotic fluid and breast milk.
Although the drug reaches breast milk, the actual concen-
tration coupled with the average feed volume suggests the
amount of drug a suckling neonate would ingest via this route
is negligible relative to the standard oral dosing regimen and
would not provide adequate antiretroviral drug concentrations
for a neonate.
Decreased lamivudine oral clearance in the neonate is likely
due to immature renal function at birth. Although glomerular
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Figure 4. Maternal virus load in pregnant HIV-1–infected women treated with lamivudine or zidovudine plus lamivudine. Mean plasma
HIV-1 levels (5SEM) determined by quantitative polymerase chain reaction are shown relative to initiation of lamivudine monotherapy (V) or
zidovudine plus lamivudine (M). Nominal lower limit: 500 copies/mL (dashed line). No. of patients per arm was not constant due to variable
times between start of therapy and birth.
filtration develops rapidly, tubular secretion can often take
1–3 months to fully develop [17, 18]. Differences in absorption
may also confound interpretation of oral clearance. The elim-
ination half-life and exposure (as measured by AUC) are in-
creased as a result of decreased lamivudine clearance relative
to pediatric patients and reflect changes in renal function, es-
pecially development of active tubular secretion during early
development. From a safety perspective, Cmax values in this
study were within the range of those seen previously (1–2 mg/
mL) as was overall exposure (20 mg/kg/day, 12,000/h/ng/mL)
in children ages 3 months–2 years [19].
Zidovudine elimination in neonates at age 1 week was sig-
nificantly increased compared to values immediately after
birth. Absorption in neonates is variable because of irregular
gastrointestinal function and irregular feeding.
Antiretroviral activity. Both lamivudine monotherapy and
lamivudine plus zidovudine combination therapy produced
rapid and substantial declines in maternal plasma HIV-1 RNA
levels beginning 24 h after initiation of zidovudine therapy. Of
importance, HIV-1 could not be detected by quantitative PCR
in any neonate at birth or at 1 or 2 weeks after birth. This
suggests either the complete absence of HIV-1 or extremely low
levels of viral replication in these neonates.
Two patients received lamivudine monotherapy ≥25 days,
and both showed an increase in virus load associated with the
selection of virus with a mutation at HIV-1 RT codon 184V.
Because it is not possible to predict precisely when labor will
start, lamivudine monotherapy cannot be relied upon to main-
tain viral suppression even during short courses of therapy, as
described here.
Lamivudine and lamivudine plus zidovudine were well-tol-
erated in women during late pregnancy and in their neonates
in this study. The adverse event profile (laboratory safety data,
adverse events) was similar to that expected in such a patient
group.
Late pregnancy did not affect lamivudine or zidovudine phar-
macokinetics, and no pharmacokinetic interaction between la-
mivudine and zidovudine was observed. Maternal zidovudine
oral clearance at 1 week postpartum was decreased. Both drugs
freely crossed the placenta and were secreted in breast milk.
Oral zidovudine therapy during labor produced maternal, cord
blood, and neonatal concentrations similar to intermittent in-
travenous and oral dosing regimens. Oral zidovudine intra-
partum dosing (300 mg at onset of labor, then every 3 h until
delivery) with lamivudine was predicted to provide average con-
centrations over a 3-h interval similar to those seen with the
continuous intravenous infusion regimen ultimately used in
ACTG 076.
A rapid reduction in virus load was seen in all mothers,
although the use of lamivudine monotherapy would be antic-
ipated to be associated with an increased risk of resistance.
Very low or no HIV-1 was detected in neonates at birth. These
data suggest that reduction in maternal virus load before
delivery and a short course of therapy to neonates may give
effective protection against HIV vertical transmission.
The recommended lamivudine pediatric dose (8 mg/kg/day)
should be reduced in neonates to 4 mg/kg/day (divided as ap-
propriate) to provide similar pediatric and adult daily exposure.
This dosage should be increased to the pediatric recommended
dosage (8 mg/kg/day) by 3 months of age, depending on renal
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function. Until further data are available for different zido-
vudine dose regimens for neonates, the recommended neo-
natal dose of 8 mg/kg/day (divided as appropriate) should be
maintained.
The combination of lamivudine plus zidovudine in short
practical oral regimens, such as used in this study, should be
investigated further in developing countries. The UNAIDS-
sponsored PETRA study in South Africa, Tanzania, and
Uganda is currently investigating the use of three regimens of
lamivudine plus zidovudine versus placebo with the aim of
identifying the most effective and applicable regimen with re-
spect to efficacy, tolerance, and cost.
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